Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer

Tumor mutation burden (TMB) serves as an effective biomarker predicting efficacy of mono-immunotherapy for non-small cell lung cancer (NSCLC). Establishing a precise TMB predicting model is essential to select which populations are likely to respond to immunotherapy or prognosis and to maximize the...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yuan, Liu, Liping, Yang, Haihong, Chen, Hanzhang, Deng, Qiuhua, Xiao, Dakai, Lin, Yongping, Zhu, Changbin, Li, Weiwei, Shao, Di, Jiang, Wenxi, Wu, Kui, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121003/
https://www.ncbi.nlm.nih.gov/pubmed/33996530
http://dx.doi.org/10.3389/fonc.2020.608989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121003/
https://www.ncbi.nlm.nih.gov/pubmed/33996530
http://dx.doi.org/10.3389/fonc.2020.608989

Ejemplares similares